1. |
Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results[J]. Br J Ophthalmol, 2010,94:297-301.
|
2. |
Sato T, Kishi S, Matsumoto H, et al. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy[J]. Am J Ophthalmol, 2013,156:95-105.
|
3. |
Inoue M, Arakawa A, Yamane S, et al. Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy[J]. Eye (Lond), 2013,27:1013-1020.
|
4. |
Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy[J]. Retina,2012,32:1453-1464.
|
5. |
Japanese Study Group of Polypoidal Choroidal Vasculopathy. Criteria for diagnosis of polypoidal choroidal vasculopathy[J].Nihon Ganka Gakkai Zasshi,2005,109:417-427.
|
6. |
Gupta B, Adewoyin T, Patel SK, et al. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration[J]. Br J Ophthalmol, 2011,95:386-390.
|
7. |
Carneiro AM, Mendonca LS, Falcao MS, et al. Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting[J]. Clin Ophthalmol, 2012,6:1149-1157.
|
8. |
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report[J]. Arch Ophthalmol, 1999,117:1329-1345.
|
9. |
Kang H, Koh H. Two-year outcome after combination therapy for polypoidal choroidal vasculopathy: comparison with photodynamic monotherapy and anti-vascular endothelial growth factor monotherapy[J]. Ophthalmologica, 2013,231:86-93.
|
10. |
Lai TY, Lee GK, Luk FO, et al. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy[J]. Retina, 2011,31:1581-1588.
|
11. |
Sato T, Kishi S, Matsumoto H, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy[J]. Am J Ophthalmol, 2010,149:947-954.
|
12. |
Rouvas AA, Papakostas TD, Ntouraki A, et al. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy[J]. Retina, 2011,31:464-474.
|